Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
(2R)-3-sulfolactate dehydrogenase (SLDH) is a bacterial and archaeal enzyme that plays a critical role in the catabolism of organosulfonates, such as sulfoquinovose and taurine-derived intermediates. It catalyzes the reversible NAD(P)+-dependent oxidation of 3-sulfolactate to 3-sulfopyruvate, a key step in pathways that allow microorganisms to extract energy and sulfur from sulfonated compounds abundant in plants and algae. In the human context, SLDH is found in specific members of the gut microbiota where its activity contributes to the production of downstream metabolites like hydrogen sulfide, which has complex implications for intestinal health and systemic metabolism. While it is not a direct target for current human pharmaceuticals, SLDH is an emerging focus in microbiome research due to its association with conditions such as obesity and inflammatory bowel disease. Structurally, SLDH is distinct from common dehydrogenases as it lacks the traditional Rossmann fold, making it a unique model for studying non-canonical oxidoreductase mechanisms.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on (2R)-3-sulfolactate dehydrogenase (SLDH).